EFFECT OF LIRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN ELDERLY PATIENTS IN THE LEADER TRIAL

被引：4
|
作者：
Gilbert, Matthew [1 ]
Bain, Stephen [1 ]
Franek, Edward [1 ]
Jodar-Gimeno, Esteban [1 ]
Nauck, Michael [1 ]
Pratley, Richard [1 ]
Rea, Rosangela [1 ]
Saraiva, Jose [1 ]
Rasmussen, Soren [1 ]
Tornoe, Karen [1 ]
von Scholten, Bernt Johan [1 ]
Buse, John B. [1 ]
机构：
[1] Novo Nordisk AS, Soborg, Denmark
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 71卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(18)32259-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A1718
引用
收藏
页码：1718 / 1718
页数：1
相关论文
共 50 条
  • [41] Safety of liraglutide vs placebo in patients with type 2 diabetes and chronic kidney disease in the LEADER trial
    Mann, J.
    Fonseca, V.
    Mosenzon, O.
    Raz, I.
    Frimer-Larsen, H.
    von Scholten, B.
    Idorn, T.
    Poulter, N.
    DIABETOLOGIA, 2018, 61 : S511 - S511
  • [42] Effect of Epoetin Dose on Mortalitiy and Cardiovascular Outcomes among Elderly Hemodialysis Patients with Diabetes
    Zhang, Yi
    Thamer, Mae
    Cotter, Dennis
    DIABETES, 2011, 60 : A368 - A368
  • [43] Long-Term Liraglutide Treatment in Elderly Diabetic Spanish Patients: Efficacy, Sustainability, Safety, and the Effect on Cardiovascular Risk Factors
    Trescoli, Carlos
    Garcia Zarco, Mar
    Bou, Ricardo
    Diaz Pujol, Encarna
    DIABETES, 2015, 64 : A678 - A678
  • [44] Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
    Nauck, Michael A.
    Ghorbani, Marie Louise Muus
    Kreiner, Eskil
    Saevereid, Hans A.
    Buse, John B.
    DIABETES CARE, 2019, 42 (10) : 1912 - 1920
  • [45] Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial
    Leiter, L. A.
    Verma, S.
    Mazer, C.
    Bain, S. C.
    Buse, J.
    Marso, S.
    Nauck, M. A.
    Zinman, B.
    Bosch-Traberg, H.
    Frimer-Larsen, H.
    Michelsen, M. M.
    Bhatt, D. L.
    DIABETOLOGIA, 2018, 61 : S356 - S357
  • [46] Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial
    Verma, S.
    Leiter, L. A.
    Mazer, C. D.
    Bain, S. C.
    Buse, J.
    Marso, S.
    Nauck, M.
    Zinman, B.
    Bosch-Traberg, H.
    Frimer-Larsen, H.
    Michelsen, M. M.
    Bhatt, D. L.
    EUROPEAN HEART JOURNAL, 2018, 39 : 598 - 598
  • [47] Effects of liraglutide versus placebo on gallbladder events: results from the LEADER trial
    Nauck, M. A.
    Saevereid, H. A.
    Ghorbani, M. L. M.
    Kreiner, E.
    Buse, J.
    DIABETOLOGIA, 2018, 61 : S352 - S352
  • [48] The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
    Dhatariya, Ketan
    Bain, Stephen C.
    Buse, John B.
    Simpson, Richard
    Tarnow, Lise
    Kaltoft, Margit Staum
    Stellfeld, Michael
    Tornoe, Karen
    Pratley, Richard E.
    DIABETES CARE, 2018, 41 (10) : 2229 - 2235
  • [49] Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
    Zinman, Bernard
    Marso, Steven P.
    Christiansen, Erik
    Calanna, Salvatore
    Rasmussen, Soren
    Buse, John B.
    DIABETES CARE, 2018, 41 (08) : 1783 - 1791
  • [50] Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
    Dai, Jhih-Wei
    Lin, Yuan
    Li, Xiu-Wei
    Tseng, Chin-Ju
    Tsai, Ming-Lung
    Yang, Ning-, I
    Hung, Ming-Jui
    Chen, Tien-Hsing
    SCIENTIFIC REPORTS, 2024, 14 (01):
12345